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Abstract
Frontotemporal Lobar Degeneration (FTLD) encompasses certain related neurodegenerative disorders which alter
behaviour, personality and language. Heterogeneous ribonuclear proteins (hnRNPs) maintain RNA metabolism and
changes in their function may underpin the pathogenesis of FTLD. Immunostaining for hnRNP A1, A2/B1 and A3
was performed on sections of temporal cortex with hippocampus from 61 patients with FTLD, stratified by pathological
hallmarks into FTLD-tau and FTLD-TDP type A, B and C subtypes, and by genetics into patients with C9orf72 expansions,
MAPT or GRN mutations, or those without known mutation. Four patients with Motor Neurone Disease (MND) with
C9orf72 expansions and 10 healthy controls were also studied. Semi-quantitative analysis assessed hnRNP staining
intensity in dentate gyrus (DG) and CA4 region of hippocampus, and temporal cortex (Tcx) in the different pathological
and genetic groups.
Immunostaining for hnRNP A1, A2/B1 and A3 revealed no consistent changes in pattern or amount of physiological
staining across any of the pathological or genetic groups. No immunostaining of any inclusions resembling
TDP-43 immunoreactive neuronal cytoplasmic inclusions or dystrophic neurites, was seen in either Tcx or DG
of the hippocampus in any of the FTLD cases investigated for hnRNP A1, A2/B1 and A3. However, immunostaining for
hnRNP A3 showed that inclusion bodies, resembling those TDP-43 negative, p62-immunopositive structures containing
dipeptide repeat proteins (DPR) were variably observed in hippocampus and cerebellum. The proportion of cases
showing hnRNP A3-immunoreactive DPR, and the number of hnRNP A3-positive inclusions within cases, was
significantly greater in DG than in cells of CA4 region and cerebellum, but the latter was significantly less in
all three regions compared to that detected by p62 immunostaining.
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Introduction
Frontotemporal Lobar Degeneration (FTLD) is a clinic-
ally, pathologically and genetically heterogeneous dis-
order affecting principally the frontal and temporal lobes
of the brain. After Alzheimer’s disease, it is the second
most common neurodegenerative disorder to affect
people before the age of 65 years. Three major syn-
dromes are recognised clinically [32]. One syndrome is
characterised by changes in behaviour and personality,
accounting for around 75% of all cases of FTLD, is
known as behavioural variant frontotemporal dementia
(bvFTD), whereas the other two syndromes are disorders
of language. Semantic dementia (SD) (also known as se-
mantic variant of primary progressive aphasia or svPPA)
is a disorder of naming and word finding, whereas Pro-
gressive Non-Fluent Aphasia (PNFA) (also known as
nfvPPA) is represented by an inability to construct
language such that speech becomes hesitant and stutter-
ing, becoming grammatically and contextually incorrect
[32]. The amyotrophic lateral sclerosis (ALS) form of
Motor Neurone Disease (MND) is seen in about 15% of
patients with bvFTD, giving FTD-MND (FTD-ALS), but
is only rarely combined with either SD or PNFA [32].
Three different pathologies can be present, all charac-
terised by abnormal neuronal, and sometimes glial, accu-
mulations of aggregated proteins. In about 45% cases,
neuronal intracytoplasmic inclusions (NCI) composed of
the microtubule associated protein, tau are seen as neuro-
fibrillary tangle-like structures (NFT) or more amorphous
tau deposits (pre-tangles) or more rounded, tau-
immunoreactive inclusions, known as Pick bodies [31].
Such cases are termed FTLD-tau [20]. In about 50% of
remaining cases [31], the RNA and DNA binding protein,
TDP-43, is present within NCI, neuritic processes (dys-
trophic neurites, DN) or neuronal intranuclear inclusions
(NII) [1, 26]; such cases are collectively termed FTLD-
TDP [20]. The proportion of each of these histological
features varies according to clinical phenotype or genetic
background, and these have been used to provide a neuro-
pathological classification of FTLD-TDP subtypes [20].
FTLD-TDP subtype A is applied when NCI and DN are
both commonly present, type B when NCI numerically
predominate over DN, type C when DN predominate over
NCI and type D when NII are most common type of
histological change. Most of the remaining 5% cases show
NCI composed of the protein, Fused in Sarcoma (FUS)
(also known as Translocation in Liposarcoma, TLS), and
known as FTLD-FUS [20].
Both TDP-43 and FUS belong to the heterogeneous
nuclear riboprotein (hnRNP) family of which there are
more than 20 members, labelled A1-U, ranging in size
from 34 to 120KDa [6, 28]. These are RNA- and DNA-
binding proteins, and serve as RNA-splicing and transcrip-
tion regulators, shuttling between nucleus and cytoplasm,
thereby controlling cellular levels of protein synthesis
[6, 28]. In the nucleus, TDP-43 binding encourages
RNA stability, whereas in the cytoplasm it associates
with stress granules and non-coding RNAs for post-
transcriptional metabolism of RNA and transport. In
FTLD-TDP there is a ‘clearing’ of normal physiological
TDP-43 from the nucleus with its accumulation within
the cytoplasmic as NCI, DN or NII [1, 26]. However, the
precise mechanism(s) directing this pathological change
remain unclear.
Other members of hnRNP family may also play a role
in the pathogenesis of FTLD, especially in patients with
expansions in C9orf72. In pull down assays, Mori et al.
reported hnRNP A3 to bind specifically to the G4C2 re-
peats, and to colocalize with dipeptide repeat protein
(DPR) inclusions by immunohistochemistry in a propor-
tion of hippocampal dentate gyrus (DG) and CA4 neu-
rons, and cerebellar granule cells [22]. In this same
study, hnRNPs A1, A2/B1 and K were also shown to
bind to the G4C2 sequence, though these did not co-
localize with NCI [22]. In a follow up study, Mori and
colleagues showed that knock-down of nuclear hnRNP
A3 lead to an increase in poly-GA, poly-GR and poly-
GP protein production with subsequent aggregation into
DPR inclusion bodies, nuclear RNA foci and mislocalisa-
tion of TDP-43 [23].
Elsewhere, Cooper-Knock et al. [8] reported co-
localisation of hnRNP A1 and hnRNP H/F with sense
RNA foci in DG granule cells in patients with expan-
sions in C9orf72. In a follow-up study, the same group
demonstrated a similar co-localisation with antisense
foci in cerebellar Purkinje cells [7]. DPR might therefore
trap hnRNPs thereby inhibiting their function. Further-
more, mutations in hnRNP A1 and A2/B1 have been
reported to cause multisystem proteinopathy and amyo-
trophic lateral sclerosis [14], but not all groups have
detected such mutations in FTLD or MND [5, 15, 30].
In the present study, we have investigated patterns of
hnRNP A1, A2/B1 and A3 immunostaining in patients
with FTLD, specifically in respect of the genetic muta-
tions and histological variants present, in order to gain
insight into understanding the role of these proteins in
driving the pathogenetic cascade. We find that a propor-
tion of DPR within the granule cells of the DG of the
hippocampus and cerebellum also contain hnRNP A3
protein in patients bearing expansions in C9orf72, and
might therefore contribute to the pathogenetic cascade
in this particular subgroup of FTLD patients.
Materials and methods
Patients
The study consisted of two sets of cases comprising 75
subjects in total. One group of 59 patients had been
recruited through Manchester Brain Bank (MBB), 55
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with a clinical diagnosis of FTLD (31 males, 24 females;
cases #1-11 and 16–59), four with a diagnosis of Motor
Neurone Disease (MND) (4 males; cases #12-15) together
with 10 healthy control subjects (three males, seven
females; cases #55-64) (see Additional file 1: Table S1).
The brains of these patients had been consecutively ac-
quired by MBB over the years 1986 to present. All patients
were from the North West of England and North Wales,
and tissues were obtained through appropriate consenting
procedures for the collection and use of the human brain
tissues. The other group of 6 patients with a clinical diag-
nosis of FTLD (two males, four females; cases #70-75)
(see Additional file 1: Table S1) was recruited through
Queens Square Brain Bank (QSBB). The brains of these
six patients had been acquired by QSBB over the years
2010 to present. All patients were from London and South
of England, and tissues were again obtained through
appropriate consenting procedures for the collection and
use of the human brain tissues. All 61 FTLD patients
fulfilled relevant clinical diagnostic criteria [12, 24, 29], 55
of which having been investigated longitudinally within
specialist dementia clinics at Salford Royal Hospital using
the Manchester Neuropsychological Profile (Man-NP)
[33, 34] to determine and characterise the nature of their
dementia. The other six patients (cases #70-75) had been
investigated at Dementia research Centre, Queen Square,
London. The four patients with MND fulfilled El Escorial
criteria [4].
Of the combined 61 FTLD patients, 30 had been
clinically diagnosed with bvFTD (14 males, 16 females;
cases #1-6,18,19,22-25,28-30,49-59,70,73-75), 13 with
bvFTD +MND (nine males, four females; cases #7-11,31-
38), 8 with PNFA (four males, four females; cases
#16,17,20,21,26,27,71,72) and 10 with SD (six males, four
females; cases #39-48) (Additional file 1: Table S1). Histo-
logically, the FTLD group comprised 25 patients with
FTLD-TDP type A (cases #1-5,16-30, 70–74), 15 with
FTLD-TDP type B (cases #6-11,31-38,75), 10 with FTLD-
TDP type C (cases #39-48) and 11 with FTLD-tau (cases
#49-59). Furthermore, within the FTLD group there were
17 patients with expansions in C9orf72 (cases #1-10,70-
75), nine with GRN mutations (cases #16-24), 10 patients
with intronic mutations in MAPT (cases #49-59) and 24
without known mutation (cases #25-48). All four patients
with MND (cases# 12–15) bore expansion in C9orf72.
Comparison of the four FTLD pathology, and MND,
patient groups showed significant differences in mean
age at onset of disease (F4,60 = 4.9, p = 0.002), mean age
at death (F4,60 = 9.1, p < 0.001) and duration of illness did
differ (F4,60 = 7.5, p < 0.001). Patients with FTLD-tau had
earlier age at onset than those with FTLD-TDP type A
and FTLD-TDP type C subgroups (p = 0.001 and 0.034,
respectively), but not compared to FTLD-TDP type B or
MND subgroups. None of the FTLD-TDP groups
differed from each other, or from MND group, in this
respect. Patients with FTLD-tau also had earlier age at
death than those with FTLD-TDP type A and FTLD-
TDP type C subgroups (p = 0.01 and 0.002, respectively),
but not compared to FTLD-TDP type B or MND sub-
groups. Patients with FTLD-TDP type B, and those with
MND, had earlier age at death than those with FTLD-
TDP-type A (p = 0.013 and p = 0.003, respectively) and
FTLD-type C (p = 0.001 and p = 0.002, respectively).
Consequently, because of their MND, patients with
FTLD-TDP type B, and those with MND, had a shorter
duration of illness than those with FTLD-type C (p = 0.001
in both instances) and FTLD-tau (p = 0.017 and p = 0.016
respectively) (Table 1). The healthy control group was also
significantly older at death (p < 0.001) than each of the
FTLD subgroups (Table 1).
Comparison of the four FTLD genetic patient groups
also showed significant differences in mean age at onset
of disease (F3,61 = 4.9, p = 0.004) and mean age at death
(F3,61 = 4.1, p = 0.010) though duration of illness did not
differ significantly (F3,61 = 2.2, p = 0.095). Patients with
MAPT mutation had earlier age at onset than those with
GRN mutation (p = 0.017) and those without known
mutation (p = 0.004), but not those with C9orf72 expansion
(p = 0.092) which in turn did not differ from GRN and no
mutation groups. Mean age at death was significantly earl-
ier in MAPT than the no mutation group (p = 0.034) but
otherwise there were no significant differences between all
other group pairings (Table 1).
Histological methods
Paraffin sections were cut at 6μm from formalin fixed
blocks of temporal lobe (BA21/22) (to include the posterior
Table 1 Selected clinical, neuropathological and genetic details
on patients studied. FTLD = Frontotemporal Lobar degeneration;
MND =Motor Neurone Disease






FTLD-TDP type A (n = 25) 14/11 61.0 ± 5.9 69.0 ± 5.1 8.0 ± 3.3
FTLD-TDP type B (n = 15) 9/6 57.1 ± 7.4 62.3 ± 8.0 5.3 ± 4.5
FTLD-TDP type C (n = 10) 6/4 59.9 ± 7.1 71.8 ± 5.7 11.9 ± 5.0
FTLD-tau (n = 11) 4/7 51.4 ± 6.4 61.4 ± 5.4 10.0 ± 3.1
MND (n = 4) 4/0 53.3 ± 7.3 56.3 ± 8.3 3.0 ± 1.4
FTLD/MND C9orf72
expansion (n = 21)
13/8 57.3 ± 6.0 63.5 ± 6.4 6.2 ± 4.1
FTLD GRN mutation
(n = 9)
5/4 60.7 ± 5.6 69.3 ± 4.1 8.7 ± 3.9
FTLD No mutation
(n = 24)
15/9 60.2 ± 7.8 68.5 ± 8.9 8.4 ± 4.9
FTLD MAPT mutation
(n = 11)
4/7 51.4 ± 6.4 61.4 ± 5.4 10.0 ± 3.1
Healthy Controls (n = 10) 3/7 na 83.3 ± 7.6 na
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hippocampus) from all 61 FTLD cases, four MND cases
and the 10 healthy control cases, and from cerebellar cor-
tex (to include dentate nucleus) of all 21 carriers of an ex-
pansion in C9orf72. Following titration (dilutions 1:100 to
1:2000) to determine optimal immunostaining, antibodies
were identically employed in a standard IHC protocol, as
described previously [9, 21]. The following antibodies were
employed: hnRNP A1 (Santa Cruz, sc374526, 1:2000),
hnRNP A2/B1 (Santa Cruz, sc374052, 1:500), hnRNP A3
(Santa Cruz, sc133665, 1:100 and Sigma AV41195, 1:150),
TDP-43 (10782-2-AP antibody, Proteintech, Manchester,
UK, 1:1000), tau (AT8, Innogenetics, Antwerp, Belgium,
1:750) and p62 (p62-lck ligand, rabbit polyclonal antibody,
B D Biosciences, Oxford, UK, 1:100) proteins. For each
antibody, antigen unmasking was performed by pressure
cooking in citrate buffer (pH 6.0, 10mM) over a 30 min
period to include warming and cooling times, reaching
123° Celsius for 30 s, and >15 psi pressure. Sections of tem-
poral cortex and hippocampus from 54/55 FTLD and all
10 control cases obtained from MBB were immunostained
using TDP-43, tau, hnRNP A1, A2 and A3 (Santa Cruz)
antibodies. Sections from six QSBB cases were immuno-
stained using TDP-43 and hnRNP A3 (Santa Cruz). Sec-
tions of hippocampus and cerebellum from all 21 carriers
of an expansion in C9orf72 from both MBB and QSBB
were additionally immunostained for p62 protein and
hnRNP A3 (Sigma antibody).
Pathological assessment
Sections were examined microscopically for the appear-
ance of intracellular distribution of immunostaining
within neurons of the temporal cortex (Tcx), DG and
CA4 region of the hippocampus and for the presence of
any hnRNP immunostained structures (NCI) resembling
those seen in TDP-43 or tau immunostaining. These
regions were chosen because Tcx and DG of the hippo-
campus are involved with TDP-43 pathology in all forms
of FTLD-TDP, or tau pathology in those patients with
MAPT mutation. Moreover, the CA4 region of the
hippocampus and cerebellar cortex were included be-
cause these are among the principal regions affected by
DPR pathology in patients with expansions in C9orf72
[4, 21]. The magnitude of physiological neuronal hnRNP
staining in each region was scored semi-quantitatively at
an objective magnification of x25 (overall magnification
of x250), employing the following rating scale:
0 = No staining present.
0.5 = rare (ie 1–5) cells per section showing weak
nuclear and/or cytoplasmic staining.
1 = 1–5 cells showing weak nuclear and/or cytoplasmic
staining per x250 microscope field.
2 = 5–10 cells showing moderate nuclear and/or
cytoplasmic staining per x250 microscope field.
3 = more than 10 cells showing strong nuclear and/or
cytoplasmic staining per x250 microscope field.
The magnitude of intraneuronal hnRNP A3 and p62
inclusion body immunostaining in areas CA4 and DG of
the hippocampus, and granule cells of the cerebellum,
was scored semi-quantitatively at an objective magnifica-
tion of x25 (overall magnification of x250), employing
the following rating scale:
0 = No inclusions present.
0.5 = rare (ie 1–5 inclusions per section).
1 = few (ie 1–5 inclusions per x250 microscope field).
2 = moderate (ie 5–10 inclusions per x250
microscope field).
3 =many (ie 10–50 inclusions per x250 microscope field).
4 = very many (ie more than 50 inclusions per x250
microscope field).
Scoring of staining for all cases and immunostains, as
presented here, was performed by a single experienced
observer (DMAM) blinded to clinical, histopathological
and genetic status. However, a subset of 20 hnRNP A2 im-
munostained cases, selected at random, to cover all patho-
logical subgroups, was chosen for scoring by a second, less
experienced, observer (AR). Independent scoring of cases
was performed by both observers and showed good agree-
ment between all pairs (κ = 0.6, p = 0.000), with 70% of
scores being the same, and no score between cases differ-
ing by more than one grade in any pairwise comparison.
Statistical analysis
Rating data was entered into an excel spreadsheet and
analyzed using Statistical Package for Social Sciences
(SPSS) software (version 17.0). The FTLD patients were
stratified according to genetic and pathological subtype
for statistical analysis of the effect of each mutation and
underlying pathology on the pattern of the staining for
each hnRNP antibody. Comparisons of semi-quantitative
scores for intensity of physiological A1 and A2/B1
hnRNP immunostaining in Tcx, DG and CA4 region of
the hippocampus, and hnRNP A3 (Sigma) and p62 in-
clusion body staining in DG and CA4 region of the
hippocampus and cerebellar cortex, were all performed
using Kruskal-Wallis test with post-hoc Mann-Whitney
test where Kruskal-Wallis yielded a significant difference
between antibody staining scores. Comparison of scores
for hnRNP A3 (Sigma) and p62 inclusion body staining
between DG and CA4 region of the hippocampus and
cerebellar cortex were made using Wilcoxon matched
pairs test. Group comparisons of age at onset, age at
death and duration of illness were made using ANOVA
with post hoc Tukey test. In all instances, significance
levels were set at p < 0.05.
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Results
TDP-43 immunostaining
TDP-43- and tau-immunostaining was employed to clas-
sify the 61 FTLD patients into their respective histo-
logical subgroups (FTLD-TDP subtypes A, B or C and
FTLD-tau) according to the form and distribution of the
TDP-43 or tau-immunoreactive inclusions (NCI, DN)
present (see Mackenzie et al. 2011 [20]). Consequently, as
would be expected when FTLD-tau and control cases were
included, the overall degree of TDP-43 immunostaining
(irrespective of histological type) differed between the five
pathological groups in both the cerebral cortex (F4,50 =
47.4, p < 0.001) and dentate gyrus (F4,50 = 48.2, p < 0.001)
with all three FTLD-TDP subtypes differing significantly
from FTLD-tau and control groups (p < 0.001 in every in-
stance). However, there were no significant differences in
the overall degree of TDP-43 immunostaining between
FTLD-TDP type A, type B and type C groups.
hnRNP A1
All FTLD (n = 54) and control (n = 10) cases studied,
showed some degree of immunostaining for hnRNP A1,
ranging from weak, through to strong, in intensity. Im-
munostaining in FTLD cases was usually nuclear and
cytoplasmic, rather than nuclear alone, though some-
times cytoplasm was predominantly immunostained
(Fig. 1a). In control cases some cytoplasmic staining was
seen, as well as the expected nuclear staining, but this
was generally weaker than observed in FTLD cases. In
the FTLD cases, there did not appear to be any obvious
group differences with respect to either the pattern of
staining across the three regions, or the range of staining
intensity achieved, between any of the pathological, or
genetic, groups.
However, semi-quantitative analysis revealed no sig-
nificant difference in scores for hnRNP A1 immuno-
staining between any of the five pathological groups for
DG (χ2 = 1.5, p = 0.833) and CA4 (χ2 = 3.9, p = 0.421)
regions of hippocampus, though there was a trend to-
wards significance in Tcx (χ2 = 9.7, p = 0.047), driven by
significantly lower scores in FTLD-TDP type C group
compared to FTLD-TDP type B (p = 0.01), FTLD-tau
(p = 0.013) and control (p = 0.015) groups. Similarly,
comparing the four genetic groups, there was a significant
difference in scores for CA4 (χ2 = 11.2, p = 0.025) region
of hippocampus, but not for DG (χ2 = 5.1, p = 0.274) and
Tcx (χ2 = 8.3, p = 0.081), driven in CA4 region by there be-
ing significantly less staining in the non-genetic group
compared to C9orf72 (p = 0.003), GRN (p = 0.031), and
MAPT (p = 0.029) groups.
No structures resembling TDP-43 immunoreactive
NCI or DN, in either Tcx or DG, or DPR immunoreac-
tive NCI in CA4 neurons, was seen on immunostaining
for hnRNP A1.
hnRNP A2/B1
Again, all FTLD (n = 54) and all control (n = 10) cases
studied, showed some degree of immunostaining for
hnRNP A2/B1. This was usually strongly nuclear
(Fig. 1b), though on occasions within the FTLD cases
both nucleus and cytoplasm were immunostained. There
did not appear to be any obvious group differences with
a b
c d
Fig. 1 Immunostaining for hnRNPs in dentate gyrus of the hippocampus in normal human brain. hnRNP A1 is localised mostly in cell cytoplasm
(a), whereas hnRNP A2 (b,c) and hnRNP A3 (d) are mostly nuclear. In cases of FTLD-TDP type C there is some ‘nuclear clearing’ of hnRNP A2
(arrowed in c). Immunoperoxidase, microscope magnification, ×400
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respect to either the pattern of staining across the three
regions, or the range of staining intensity achieved,
between any of the pathological, or genetic, groups.
However, it was noted that some cases of FTLD-TDP
type C showed a clearing of nuclear staining from some
of the cells within DG (Fig. 1c).
Semi-quantitative analysis also revealed no significant
difference in scores for hnRNP A2/B1 immunostaining be-
tween any of the five pathological (Tcx, χ2 = 9.1, p = 0.058;
DG, χ2 = 1.5, p = 0.833; CA4, χ2 = 3.9, p = 0.421) or four
genetic (Tcx, χ2 = 6.4, p = 0.171; DG, χ2 = 2.3, p = 0.672;
CA4, χ2 = 3.0, p = 0.553) groups.
Again, no structures resembling TDP-43 immunoreac-
tive NCI or DN, in either TCX or DG, or DPR immunore-
active NCI in CA4 neurons, was seen on immunostaining
for hnRNP A/B1.
hnRNP A3
No immunostaining was obtained in any case, FTLD or
control, when using the Santa Cruz hnRNP A3 antibody,
at all antibody dilutions tested (1:50–1:500). However,
when Sigma hnRNP A3 antibody was used on a selection
of the FTLD and control cases, which included all cases
bearing expansions in C9orf72 and representative cases
from the other FTLD groups, some degree of immuno-
staining for hnRNP A3 was seen in most instances. This
was usually nuclear (Fig. 1d), ranging from very weak to
moderately strong, though on rare occasions within
FTLD cases both nucleus and cytoplasm was immuno-
stained. There did not appear to be any obvious group
differences with respect to either the pattern of nuclear
or cytoplasmic staining across Tcx and hippocampus, or
the range of staining intensity achieved, between any of
the pathological or genetic groups. No semi-quantitative
comparisons between pathological or genetic groups
were performed, as the number of cases examined over-
all, particularly those not bearing expansion in C9orf72,
was insufficient for meaningful statistical analysis.
No immunostaining of any inclusions resembling
TDP-43 immunoreactive NCI or DN, was seen in either
Tcx or DG of the hippocampus in any of the FTLD cases
investigated. However, immunostaining for hnRNP A3
showed that inclusion bodies, resembling those p62-
immunoreactive structures (NCI) containing DPR
(Fig. 2a-c), were variably present in the hippocampus
and cerebellum (Fig. 2d-f). NCI were most often, but nu-
merically only sparsely, observed in granule cells of the
DG in 17/21 cases bearing expansions in C9orf72 (Fig. 2d),
and were only rarely seen in cells of CA4 region of the
hippocampus in 1/21 cases (Fig. 2e), and not at all in gran-
ule cells of the cerebellum in 12/21 cases (Fig. 2f), though
very rarely isolated NCI were seen in the other nine cases.
Hence, the proportion of cases showing DPR in granule
cells of DG was significantly greater than that for cells of
CA4 region (χ2 = 24.9; p = <0.001) or cerebellum (χ2 = 8.4;
p = <0.003), with the proportion of cases showing DPR in
cerebellum being greater than that of CA4 neurons
(χ2 = 6.5; p = <0.01).
While the overall scores for the numerical severity of
p62 positive inclusions (DPR) did not significantly differ
between granule cells of DG, CA4 region and cerebellum
(χ2 = 2.95, p = 0.228), the scores for those which were
A3-immunoreactive did differ significantly (χ2 = 31.2,
p = 0.000) with the scores for A3-positive inclusions
in cells of DG being greater than those in CA4 region
(p = 0.000) and cerebellum (p = 0.000), and those for
the cerebellum being greater than those for CA4 region
(p = 0.000). The number of inclusions seen on hnRNP A3
immunostaining was clearly much less than that seen on
p62 immunostaining across all three regions (Fig. 2). Ac-
cordingly, semi-quantitative analysis revealed significantly
lower scores for hnRNP A3 inclusion body staining, com-
pared to that of p62 immunostaining, for DG granule cells
in hippocampus (p = 0.000) and cerebellum (p = 0.000)
and for CA4 neurones of the hippocampus (p = 0.000).
Discussion
In the present study, we have investigated the pattern of
hnRNP A1, A2/B1 and A3 immunostaining across a
range of clinical, pathological and genetic forms of
FTLD and MND. Microscopically, there appeared to be
increased cytoplasmic staining for hnRNP A1, and to a
lesser extent hnRNP A2/B1, across each of the FTLD
pathological or genetic groups. While this might reflect
an increased physiological expression of these hnRNPs,
it could also represent a cellular re-localisation of pro-
tein from nucleus to cytoplasm. However, given the wide
range of semi-quantitative scores for hnRNP A1 and A2/
B1 across each of the pathological groups, the micro-
scopic observations could not be substantiated by semi-
quantitative statistical analysis. Nonetheless, Gami-Patel
and colleagues also noted an increased cytoplasmic
staining of hnRNP A1 in cases with FTLD-FUS [11]. To-
gether, these data suggest there might be a derangement
of movement of hnRNP A1, and other hnRNP proteins,
across all pathological forms of FTLD beyond that in-
volving just TDP-43 or FUS.
No immunoreactive structures, resembling those seen
in FTLD cases on tau or TDP-43 immunostaining, were
seen following immunostaining for hnRNP A1, A2/B1 or
A3, consistent with previous findings [11]. Such
observations would be consistent with genetic studies
showing that mutations in hnRNP A1 and hnRNP A2/
B1 genes, which might be anticipated to result in
molecular or pathological changes, are extremely rare
events in both FTLD and MND [5, 14, 15, 30]. Interest-
ingly, on the other hand, a proportion of FUS-positive
inclusions in FTLD-FUS, especially cases of the
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form of FTLD-FUS, have been reported to contain
hnRNP A1 protein, along with other hnRNPs to a lesser
extent [25]. This finding would be consistent with stud-
ies showing disruption of FET proteins, transportin-1
(TRN1), TAF15 and EWS in FTLD-FUS [3, 10], given
that hnRNP A1 can act as a cargo protein for TRN1 in
TRN1-mediated nuclear import [16].
However, when using Sigma hnRNP A3 antibody, NCI
resembling those seen with p62 or DPR immunostaining
were variably seen in granule cells of DG of the hippo-
campus in 17/21 FTLD cases with C9orf72 expansion,
but only rarely so in a single case in neurons of CA4
region. hnRNP A3 immunoreactive inclusions were also
very rarely seen in cerebellum in 9/21 cases. Semi-
quantitative comparisons showed that the number of
hnRNP A3 immunoreactive inclusions was significantly
less than those seen on p62 immunohistochemistry of
the same cases in all three regions.
To our knowledge there has only been three previous
studies investigating the role of hnRNP A3 in FTLD
[22, 23]. In 2013, Mori and colleagues reported hnRNP
A3 to bind specifically to G4C2 repeats in pull down
assays, and to colocalize by immunohistochemistry with
p62/DPR NCI in a proportion of hippocampal DG and
CA4 neurons, and cerebellar granule cells [22]. As we
have found here, Mori et al. noted that the number of
A3 immunoreactive NCI was significantly less than
those detected by p62 immunostaining in these same
brain regions, with DG granule cells again showing the
greatest number of NCI and CA4 neurons the least
[22]. Although hnRNPs A1, A2/B1 and K were also
shown to bind to the G4C2 sequence in pull down assays,
these did not co-localize with NCI by immunohistochem-
istry [22]. However, in this particular study there were
some patients with FTLD-TDP, but without C9orf72 ex-
pansion, who also showed rare hnRNP A3-containing
neurites, but not inclusion bodies, suggesting that hnRNP
A3 dysfunction, as well as other hnRNPs, could play a
wider role in mRNA deregulation and the pathophysiology
of FTLD. In the later study [23], hnRNP A3 was found to
co-localise with a proportion of poly-GA contain DPR in
hippocampal DG granule cells. Moreover, poly-GA DPR
were over 50% higher in cases with low nuclear hnRNP
A3 expression compared to cases with high expression
[23]. Recently, Boeynaems et al. also observed hnRNP A3
immunostaining of a few DPR in DG granule cells in six
patients with C9orf72 associated FTLD [2].
The present study is consistent with these previous
findings [2, 22, 23] as regards both the pattern of immu-
nostaining for hnRNP A1 and A2/B1, and the presence
of hnRNP A3 immunoreactivity in a subset of hippo-
campal and cerebellar DPR containing NCI and its rela-
tionship to p62 and DPR (poly-GA) immunostaining.
However, in contrast to Mori et al. [22], we did not find
hnRNP A3 immunostaining of other structures such as
NCI, DN or NII in any other FTLD cases despite inten-
sive survey.
hnRNP A3 is a member of the hnRNP A/B family of
RNA-binding proteins that, in common with other
a b c
d e f
Fig. 2 Immunostaining for p62 (a-c) and hnRNP A3 (d-f) in dentate gyrus (a,d) and CA4 region (b,e) of hippocampus, and in cerebellum (c,f), in
cases of FTLD-TDP associated with expansions in C9orf72 gene. There are abundant p62-immunoreactive neuronal cytoplasmic inclusions in dentate
gyrus (a) and CA4 region (b) of hippocampus, and in cerebellum (c), though only a small proportion of cells in dentate gyrus show similar appearing
hnRNP A3-immunoreactive inclusions (arrowed in d), but none are present in CA4 region (e) or cerebellum (f). Immunoperoxidase, microscope
magnification, ×400
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RNA-binding proteins, contains two N-terminal RNA
recognition sites followed by a C-terminal glycine rich
region [13]. This family of proteins shuttle between
nucleus and cytoplasm and perform multiple functions
in terms of pre-mRNA splicing, nuclear import and
cytoplasmic trafficking of mRNA, mRNA stability and
turnover, and translation [27]. In brain and neuronal cell
lines, hnRNP A3 is found mainly in the nucleus, less so
within cytoplasm [19]. In keeping with these experimen-
tal findings, in the present study, we observed hnRNP
A3 immunostaining mainly in the nucleus, though this
was highly variable with nuclei densely staining in some
cases but remaining unstained in others. There appeared
to be no consistent staining pattern across different
disease or control states suggesting that this lack of con-
sistent stainability may represent a technical, rather than
physiological, change. However, against this, we noted a
consistent moderate to strong nuclear staining for
hnRNP A1 and A2/B1, even in those cases where there
was no nuclear staining for hnRNP A3. Hence, it is still
not clear whether this lack of staining represents a
physiological/pathological clearance of nuclear protein
or whether it reflects variable preservation of antigen in
post mortem brain.
Because Mori et al. found hnRNP A3 to bind directly
to G4C2 repeats [22], and because hnRNP A3 is known
to act in RNA export [19], it is possible that an aberrant
export of C9orf72 pre-mRNA, or the non-ATG transla-
tion thereof, could be triggered specifically by an in-
creased binding of hnRNP A3. This might explain why
this member of hnRNP A/B family is associated with
DPR, whereas hnRNP A1 and A2/B1 are not associated
with DPR even though they are able to bind to the
G4C2 sequence in pull down assays [22]. However, if
this is so, it remains unclear why only a proportion of
p62-immunoreactive DPR apparently contain hnRNP A3
protein, at least as can be detected immunohistochemi-
cally, and why the proportion of cells and cell types
displaying hnRNP A3 immunostaining in cases with
C9orf72 expansions varies so widely. Mori et al. [23] also
noted that reduced hnRNPA3 expression in C9orf72 cases
leads to increased levels of the repeat RNA as well as en-
hanced production and deposition of DPR proteins and
RNA foci. Hence, reductions in physiological levels of
hnRNP A3, consequent to binding to DPR, might also fa-
cilitate production of RNA foci, as well as DPR formation.
The exact (chemical) nature of the binding between
hnRNP A3 and DPR is unclear. DPRs (and RNA foci)
cause dysfunction of nucleocytoplasmic transport and
result in hnRNP A3 mislocalization. HnRNP A3 may
then gather in stress granules and combine with arginine
rich poly GR/PR DPR species through interaction at its
low complexity sequence [17, 18]. Nonetheless, this does
not account for hnRNP A3-specific colocalization with
DPR aggregates since hnRNPA1 and A2/B1 are also
partners in the poly GR/PR interactome [17, 18]. How-
ever, the glycine-rich low complexity domain of hnRNP
A3 is much longer than that of hnRNP A1 and hnRNP
A2/B1, and might thus make hnRNP A3 more prone to
aggregate. Once trapped by DPR in stress granules, it is
then p62-labeled for degradation via the proteasome.
Conclusions
In summary, in the present study, we have shown
that at least a proportion of TDP-43-negative, p62-
immunoreactive DPR contain hnRNP A3 protein in
cases with C9orf72 expansions. No other members of
hnRNP A/B family were seen to be present in such inclu-
sions. Present data therefore suggest a specific relationship
between hnRNP A3 and DPR in inclusion body formation,
rather than a simple passive recruitment of hnRNP A3
protein into the aggregating protein conglomerate. The
lack of hnRNP A1 and A2/B1 within DPR would be in
keeping with such an ‘active recruitment’ of hnRNP A3
into DPR, and the lack of these former hnRNPs in TDP-
43 aggregates, while being associated with FUS aggregates
(for hnRNP A1 at least), points to important and specific
roles for the different hnRNPs in the pathogenesis of the
different forms of FTLD.
Additional file
Additional file 1: Selected clinical, pathological and genetic details on
cases studied. (XLSX 17 kb)
Acknowledgements
We acknowledge the support of the Manchester Brain Bank by Alzheimer’s
Research UK and Alzheimer’s Society through their funding of the Brains for
Dementia Research (BDR) Programme. Manchester Brain Bank also receives
Service Support costs from Medical Research Council. This study was
supported in part by funding from Medical research Council of UK, grant
number G0701441. We also thank NOMIS Foundation which supports FTD
research by CH in Munich laboratory. TL is funded by an Alzheimer’s
Research UK Senior Fellowship. BCB was supported by the Leonard Wolfson
Centre for Experimental Neurology. The Queen Square Brain Bank is
supported by the Reta Lila Weston Institute for Neurological Studies and the
Progressive Supranuclear Palsy (Europe) Association and the Rosetrees Trust.
Authors’ contributions
YD and LF performed all immunohistochemical staining, AR provided
technical support and carried mout all statistical analyses, YN, KM and CH
provided hnRNP A3 antibody and assisted with review of the manuscript. SR
and SPB provided genetic anlyses, BCB and TL provided technical help and
advice concerning London cases and assisted with writing of the paper. AR,
MJ and JSS helped with patient characterization and review of the
manuscript. DMAM conceived the study, performed the semiquantitative
assays, prepared the figures and wrote and revised the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Davidson et al. Acta Neuropathologica Communications  (2017) 5:31 Page 8 of 10
Author details
1Division of Neuroscience and Experimental Psychology, School of Biological
Sciences, Faculty of Biology, Medicine and Health, University of Manchester,
Salford Royal Hospital, Salford M6 8HD, UK. 2Biomedical Centre (BMC),
Biochemistry, Ludwig-Maximilians Universitat Munchen, Munich, Germany.
3Department of Psychiatry, Osaka University Graduate School of Medicine,
Osaka, Japan. 4Division of Neuroscience and Experimental Psychology,
School of Biological Sciences, Faculty of Biology, Medicine and Health,
University of Manchester, A V Hill Building, Manchester M13 9PT, UK.
5Cerebral Function Unit, Greater Manchester Neurosciences Centre, Salford
Royal Hospital, Stott Lane, Salford M6 8HD, UK. 6Department of Molecular
Neuroscience, University College London, Institute of Neurology, Queen
Square Brain Bank for Neurological Disorders, 1 Wakefield St, London WC1N
1PJ, UK. 7German Centre for Neurodegenerative Diseases (DZNE) Munich,
Munich, Germany. 8Munich Cluster for Systems Neurology (SyNergy), Munich,
Germany.
Received: 22 March 2017 Accepted: 12 April 2017
References
1. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K,
Yoshida M, Hashizume Y, Oda T (2006) TDP-43 is a component of ubiquitin-
positive tau-negative inclusions in frontotemporal lobar degeneration and
amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602–611.
2. Boeynaems S, Bogaert E, Michiels E, Gijselinck I, Sieben A, Jovičić A, De
Baets G, Scheveneels W, Steyaert J, Cuijt I, Verstrepen KJ, Callaerts P,
Rousseau F, Schymkowitz J, Cruts M, Van Broeckhoven C, Van Damme
P, Gitler AD, Robberecht W, Van Den Bosch L (2016) Drosophila screen
connects nuclear transport genes to DPR pathology in c9ALS/FTD. Sci
Rep 6:20877.
3. Brellstaff J, Lashley T, Holton JL, Lees AJ, Rossor MN, Bandopadhyay R, Revesz T
(2011) Transportin-1: a marker of FTLD-FUS. Acta Neuropathol 122:591–600
4. Brooks B (1994) El Escorial World Federation of Neurology criteria for the
diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron
Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology
Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits
of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci
124(suppl):96–107.
5. Calini D, Corrado L, Del Bo R, Gagliardi S, Pensato V, Verde F, Corti S, Mazzini
L, Milani P, Castellotti B, Bertolin C, Sorarù G, Cereda C, Comi GP, D'Alfonso
S, Gellera C, Ticozzi N, Landers JE, Ratti A, Silani V, SLAGEN Consortium (2013)
Analysis of hnRNPA1, A2/B1, and A3 genes in patients with amyotrophic lateral
sclerosis. Neurobiol Aging 34:2695.e11–2.
6. Chaudhury A, Chander P, Howe PH (2010) Heterogeneous nuclear
ribonucleoproteins (hnRNPs) in cellular processes: Focus on hnRNP E1's
multifunctional regulatory roles. RNA 16:1449–1462.
7. Cooper-Knock J, Higginbottom A, Stopford MJ, Highley RJ, Ince PG, Wharton SB,
Wilson SA, Pickering-Brown S, Kirby J, Hautbergue GM, Shaw PJ (2015) Antisense
RNA foci in the motor neurones of C9ORF72-ALS patients are associated with
TDP-43 proteinopathy. Acta Neuropathol 130:63–75
8. Cooper-Knock J, Walsh MJ, Higginbottom A, Highley RJ, Dickman MJ, Edbauer
D, Ince PG, Wharton SB, Wilson SA, Kirby J, Hautbergue GM, Shaw PJ (2014)
Sequestration of multiple RNA recognition motif-containing proteins by C9orf72
repeat expansions. Brain 137:2040–2051.
9. Davidson Y, Barker H, Robinson AC, Troakes C, Smith B, Al-Saraj S, Shaw C,
Rollinson S, Masuda-Suzukake M, Hasegawa M, Pickering-Brown S, Snowden
JS, Mann DMA (2014) Brain distribution of dipeptide repeat proteins in
Frontotemporal Lobar Degeneration and Motor Neurone Disease associated
with expansions in C9ORF72. Acta Neuropathol Comm 2:70.
10. Davidson YS, Robinson AC, Hu Q, Mishra M, Baborie A, Jaros E, Perry RH,
Cairns NJ, Richardson A, Gerhard A, Neary D, Snowden JS, Bigio EH, Mann
DM (2013) Nuclear carrier and RNA binding proteins in Frontotemporal
Lobar Degeneration associated with Fused in Sarcoma (FUS) pathological
changes. Neuropathol Appl Neurobiol 39:157–165.
11. Gami-Patel P, Bandopadhyay R, Brelstaff J, Revesz T, Lashley T (2016) The
presence of heterogeneous nuclear ribonucleoproteins in Frontotemporal
Lobar degeneration with FUS-positive inclusions. Neurobiol Aging 46:192–203
12. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF,
Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF,
Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges
JR, Mesulam MM, Grossman M (2011) Classification of primary progressive
aphasia and its variants. Neurology 76:1006–1014.
13. He Y, Smith R (2009) Nuclear functions of heterogeneous nuclear ribonuclear
proteins A/B. Cell Mol Life Sci 66:1239–1256.
14. Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, MacLea KS,
Freibaum B, Li S, Molliex A, Kanagaraj AP, Carter R, Boylan KB, Wojtas AM,
Rademakers R, Pinkus JL, Greenberg SA, Trojanowski JQ, Traynor BJ, Smith
BN, Topp S, Gkazi AS, Miller J, Shaw CE, Kottlors M, Kirschner J, Pestronk A,
Li YR, Ford AF, Gitler AD, Benatar M, King OD, Kimonis VE, Ross ED, Weihl
CC, Shorter J, Taylor JP (2013) Mutations in prion-like domains in hnRNPA2B1
and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495:467–473
15. Le Ber I, Van Bortel I, Nicolas G, Bouya-Ahmed K, Camuzat A, Wallon D, De
Septenville A, Latouche M, Lattante S, Kabashi E, Jornea L, Hannequin D,
Brice A, French research Network on FTLD/FTLD-ALS (2014) hnRNPA2B1 and
hnRNPA1 mutations are rare in patients with "multisystem proteinopathy"
and frontotemporal lobar degeneration phenotypes. Neurobiol Aging
35:934.e5–6.
16. Lee BJ, Cansizoglu AE, Suel KE, Louis TH, Zhang Z, Chook YM (2006) Rules
for nuclear localisation sequence recognition by karyopherinβ2. Cell 126:
543–558.
17. Lee KH, Zhang P, Kim HJ, Mitrea DM, Sarkar M, Freibaum BD, Cika J, Coughlin
M, Messing J, Molliex A, Maxwell BA, Kim NC, Temirov J, Moore J, Kolaitis RM,
Shaw TI, Bai B, Peng J, Kriwacki RW, Taylor JP (2016) C9orf72 dipeptide repeats
impair the assembly, dynamics, and function of membrane-less organelles. Cell
167:774–788.e17.
18. Lin Y, Mori E, Kato M, Xiang S, Wu L, Kwon I, McKnight SL (2016) Toxic PR
poly-dipeptides encoded by the C9orf72 repeat expansion target LC domain
polymers. Cell 167:789–802.e12.
19. Ma AS, Moran-Jones K, Shan J, Munro TP, Snee MJ, Hoek KS, Smith R (2002)
Heterogeneous nuclear ribonuclearprotein A3, a novel RNA trafficking
response-element protein. J Biol Chem 277:18010–18020.
20. Mackenzie IRA, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E,
Perry RH, Trojanowski JQ, Mann DMA, Lee VM-Y (2011) A harmonized
classification system for FTLD-TDP pathology. Acta Neuropathol 122:111–113.
21. Mann DMA, Rollinson S, Robinson A, Callister J, Snowden JS, Gendron
T, Petrucelli L, Masuda-Suzukake M, Hasegawa M, Davidson YS, Pickering-Brown
S (2013) Dipeptide repeat proteins are present in the p62 positive inclusions in
patients with Frontotemporal Lobar Degeneration and Motor Neurone Disease
associated with expansions in C9ORF72. Acta Neuropathol Comm 1:68.
22. Mori K, Lammich S, Mackenzie IRA, Forne I, Zilow S, Kretzschmar H, Edbauer
D, Jannssens J, Kleinberger G, Cruts M, Herms J, Neumann M, Van Broekhoven
C, Arzberger T, Haass C (2013) hnRNP A3 binds to GGGGCC repeats and is a
constituent of p62-positive/TDP-43 negative inclusions in the hippocampus of
patients with C9orf72 mutations. Acta Neuropathol 125:413–423.
23. Mori K, Nihei Y, Arzberger T, Zhou Q, Mackenzie IR, Hermann A, Hanisch F,
German Consortium for Frontotemporal Lobar Degeneration; Bavarian Brain
Banking Alliance, Kamp F, Nuscher B, Orozco D, Edbauer D, Haass C (2016)
Reduced hnRNPA3 increases C9orf72 repeat RNA levels and dipeptide-repeat
protein deposition. EMBO Rep 17:1314–1325.
24. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M,
Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF
(1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic
criteria. Neurology 51:1546–1554.
25. Neumann M, Igaz LM, Kwong LK, Nakashima-Yasuda H, Kolb SJ, Dreyfuss G,
Kretzschmar HA, Trojanowski JQ, Lee VM (2007) Absence of heterogeneous
nuclear ribonucleoproteins and survival motor neuron protein in TDP-43
positive inclusions in frontotemporal lobar degeneration. Acta Neuropathol
113:543–548.
26. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Bruce J, Schuck
T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie
IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM
(2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and
amyotrophic lateral sclerosis. Science 314:130–133.
27. Papadopoulou C, Boukakis G, Ganou V, Patrinou-Georgoula M, Guialis A
(2012) Expression profile and interactions of hnRNP A3 within hnRNP/
mRNP complexes in mammals. Arch Biochem Biophys 523:151–160
28. Piñol-Roma S, Choi YD, Matunis MJ, Dreyfuss G (1988) Immunopurification
of heterogeneous nuclear ribonucleoprotein particles reveals an assortment
of RNA-binding proteins. Genes Dev 2:215–227.
29. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van
Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF,
Davidson et al. Acta Neuropathologica Communications  (2017) 5:31 Page 9 of 10
Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H,
Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN,
Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S,
Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg
Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller
BL (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of
frontotemporal dementia. Brain 134:2456–2471.
30. Seelen M, Visser AE, Overste DJ, Kim HJ, Palud A, Wong TH, van Swieten JC,
Scheltens P, Voermans NC, Baas F, de Jong JM, van der Kooi AJ, de Visser M,
Veldink JH, Taylor JP, Van Es MA, van den Berg LH (2014) No mutations in
hnRNPA1 and hnRNPA2B1 in Dutch patients with amyotrophic lateral
sclerosis, frontotemporal dementia, and inclusion body myopathy. Neurobiol
Aging 35:1956.e9–1956.e11.
31. Shi J, Shaw CL, Richardson AMT, Bailey K, Tian J, Varma AR, Neary D, Snowden
JS, Mann DMA (2005) Histopathological changes underlying frontotemporal
lobar degeneration with clinicopathological correlation. Acta Neuropathol 110:
501–512.
32. Snowden JS, Neary D, Mann DMA (2005) Frontotemporal dementia. Lancet
Neurol 4:771–780.
33. Snowden JS, Thompson JC, Stopford CL, Richardson AMT, Gerhard A, Neary
D, Mann DMA (2011) The clinical diagnosis of early-onset dementias:
diagnostic accuracy and clinicopathological relationships. Brain 135:693–708
34. Thompson JC, Stopford CL, Snowden JS, Neary D (2005) Qualitative
neuropsychological performance characteristics in frontotemporal dementia
and Alzheimer’s disease. J Neurol Neurosurg Psychiatr 76:920–927.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Davidson et al. Acta Neuropathologica Communications  (2017) 5:31 Page 10 of 10
